KumarKL. Recent advances in the acute management of migraine and cluster headaches. J Gen Intern Med1994; 9: 339–48.
2.
SilbersteinSDSaperJD. Migraine. In: DalessioDJSilbersteinSD, eds. Wolff's headache and other head pain. 6th ed. New York: Oxford University Press, 1993: 96–170.
3.
Tfelt-HansenPLiptonRB. Dihydroergotamine. In: OlesenJTfelt-HansenPWelchKMA, eds. The headaches. New York: Raven Press, 1993: 323–7.
4.
TouchonJAshfordEAPilgrimAS. A comparison of sc sumatriptan and intranasal dihydroergotamine (DHE) in the treatment of migraine (abstract). Neurology1995; 45: A378–9.
5.
Drugs for migraine. Med Lett Drugs Ther1995; 37: 17–20.
6.
SilbersteinSD. Pharmacological management of cluster headache. CNS Drugs1994; 2: 199–207.
7.
AnderssonPGJespersenLT. Dihydroergotamine nasal spray in the treatment of attacks of cluster headache. Cephalgia1996; 6: 51–4.
8.
PloskerGLMcTavishD. Sumatriptan. A reappraisal of its pharmacology and its therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs1994; 47: 622–51.
9.
The Oral Sumatriptan International Multiple Dose Study Group. Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. Eur Neurol1991; 31: 306–13.
10.
Multinational Oral Sumatriptan and Cafergot Comparative Study Group. A randomized, double-blind comparison of sumatriptan and Cafergot in the acute treatment of migraine. Eur Neurol1991; 31: 314–22.
11.
Oral Sumatriptan and Aspirin plus Metoclopramide Comparative Study Group. A study to compare oral sumatriptan with oral aspirin plus oral metoclopramide in the acute treatment of migraine. Eur Neurol1992; 32: 177–84.
12.
JensenRBrinckTOlesenJ. Sodium valproate has a prophylactic effect in migraine without aura: a triple-blind, placebo-controlled, crossover study. Neurology1994; 44: 647–51.
13.
HeringRKuritzkyA. Sodium valproate has a prophylactic effect in migraine: a double-blind study vs placebo. Cephalgia1992; 12: 81–4.
14.
RothrockJFKellyNMBrodyMLGolbeckA. A differential response to treatment with divalproex sodium in patients with intractable headache. Cephalgia1994; 14: 241–4.
15.
MatthewNTSaperJRSilbersteinSDRankinLMarkleyHGSolomonS. Migraine prophylaxis with divalproex. Arch Neurol1995; 52: 281–6.
16.
BaumelB. Migraine: a pharmacological review with newer options and delivery modalities. Neurology1994; 44 (suppl 3): S 13–7.
17.
AdelmanJUVonseggernRV. Cost consideration in headache treatment, Part I. Prophylactic migraine treatment. Headache1995; 35: 479–87.
18.
US Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology1993; 43: 2292–8.
19.
UK Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet1990; 335: 1114–7.
20.
GidalBEMalyMMBuddeJPitterleMELensmeyerGJonesJC. Effect of a high protein meal on gabapentin pharmacokinetics. Epilepsy Res1996; 23: 71–6.
21.
MellickLBMellickGA. Successful treatment of reflex sympathetic dystrophy with gabapentin (letter). Am J Emerg Med1995; 13: 96.
22.
MellickGASengML. The use of gabapentin in the treatment of reflex sympathetic dystrophy and a phobic disorder. Am J Pain Manage1995; 5: 7–9.
23.
SanderJWASPatsalosPNOxleyJRHamiltonMJYuenWC. A randomized double-blind, placebo-controlled, add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Res1990; 6: 221–6.
24.
MatsuoFBergenDFaughtEMessenheimerJADrenATRuddGD. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology1993; 43: 2284–91.
25.
TimmingsPLRichensA. Lamotrigine as an add-on drug in the management of Lennox-Gastaut syndrome. Eur Neurol1992; 32: 305–7.
26.
BrodieMJRichensAYuenAW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet1995; 345: 476–9.
27.
StablesJPBialerMJohannessenSIKupferbergHJLevyRHLoiseauP. Progress report on new antiepileptic drugs. A summary of the Second Eilat Conference. Epilepsy Res1995; 22: 235–46.
28.
BrowneTRKuglerAREldonMA. Pharmacology and pharmacokinetics of fosphenytoin. Neurology1996; 46 (suppl l): S3–7.
29.
UthmanBMWilderBJRamsayRE. Intramuscular use of fosphenytoin: an overview. Neurology1996; 46 (suppl l): S24–8.
30.
Goodkin DE. Interferon β-lb. Lancet1994; 344: 1057–60.
31.
The INFB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Interferon beta-lb in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology1995; 45: 1277–85.
32.
Quality Standards Subcommittee of the American Academy of Neurology. Practice advisory on selection of patients with multiple sclerosis for treatment with betaseron. Neurology1994; 44: 1537–40.
33.
JacobsLDCookfairDLRudickRAHerndonRMRichertJRSalazarAM. Intramuscular interferon beta-1 a for disease progression in relapsing multiple sclerosis. Ann Neurol1996; 39: 285–94.
34.
JohnsonKPBrooksBRCohenJAFordCCGoldsteinJLisakRP. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a Phase III multicenter, double-blind, placebo-controlled trial. Neurology1995; 45: 1268–76.
35.
BeverCT. The current status of studies of aminopyridines in patients with multiple sclerosis. Ann Neurol1994; 36 (suppl): S118–21.
36.
PennRDSavoySMCorcosDLatashMGottliebGParkeB. Intrathecal baclofen for severe spinal spasticity. N Engl J Med1989; 320: 1517–21.
37.
SavoySMGianinoJM. Intrathecal baclofen infusion: an innovative approach for controlling spinal spasticity. Rehabil Nurs1993; 18: 105–13.
